Gabelli Funds LLC Has $25.75 Million Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Gabelli Funds LLC boosted its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 245.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 456,147 shares of the company’s stock after buying an additional 324,147 shares during the period. Gabelli Funds LLC’s holdings in Catalent were worth $25,749,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Lindbrook Capital LLC raised its position in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after buying an additional 208 shares during the period. Czech National Bank raised its position in Catalent by 0.7% during the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after buying an additional 228 shares during the period. BNP Paribas Asset Management Holding S.A. raised its position in Catalent by 1.9% during the fourth quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after buying an additional 328 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in Catalent by 6.2% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after buying an additional 331 shares during the period. Finally, Arizona State Retirement System raised its position in Catalent by 0.7% during the fourth quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock valued at $2,226,000 after buying an additional 365 shares during the period.

Insider Activity at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the transaction, the insider now owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Matti Masanovich sold 2,993 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the transaction, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ricky Hopson sold 1,401 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the transaction, the insider now directly owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The disclosure for this sale can be found here. 0.31% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

CTLT has been the topic of several recent analyst reports. Stephens reissued an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. StockNews.com assumed coverage on Catalent in a research report on Wednesday. They issued a “sell” rating on the stock. Finally, Barclays upped their target price on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $55.65.

Catalent Stock Up 0.4 %

Shares of CTLT traded up $0.23 during trading hours on Friday, hitting $58.68. 3,004,922 shares of the company were exchanged, compared to its average volume of 1,818,650. The company has a market cap of $10.62 billion, a PE ratio of -9.62, a PEG ratio of 2.41 and a beta of 1.16. The firm’s 50 day moving average is $56.21 and its 200-day moving average is $55.69. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $60.20. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. On average, equities research analysts forecast that Catalent, Inc. will post -0.17 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.